CERENOME, INC. 10-Q

Item 1 . Legal Proceedings None. 33 Table of Contents Item 1A. Ris k Factors There have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025. Item 2. Unregistered Sal es of Equity Securities and Use of Proceeds 2(a): Unregistered Sales of Equity Securities and Use of Proceeds None. 2(b): Use of Proceeds from Registered Securities None. 2(c): Purchases of Equity Securities The following table provides certain information with respect to the Company's purchases of its common stock for the three months ended March 31, 2026. Company Purchases of Common Stock Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased As Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares That May Yet Be Purchased Under Plans or Programs (1) January 1 - 31, 2026 272,821 $ 16.50 272,821 $ - February 1 - 28, 2026 - $ - - $ - March 1 - 31, 2026 - $ - - $ - Total 272,821 $ - 272,821 $ - (1) On March 4, 2025, the Company entered into the March 2025 SPA with the March 2025 Private Placement Purchasers for the March 2025 Private Placement . On June 17, 2025, the Company and the Purchasers entered into the Letter Agreement with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement and provided for the return and cancellation of Private Placement Shares and Pre-Funded Warrants. The Private Placement Shares and Pre-Funded Warrants were repurchased by the Company pursuant to the Letter Agreement. Refer to Note 12 Stockholders’ Equity in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Letter Agreement.